摘要
目的观察龟羚帕安丸对帕金森病(PD)大鼠神经干细胞(NSCs)移植后中脑黑质的细胞存活数以及核受体相关因子1(Nurr1)、音猥因子(Shh)蛋白表达的影响。方法采用6-羟基多巴(6-OHDA)注射法建立PD大鼠模型,将60只造模成功大鼠随机分为空白对照组,移植对照组,美多芭组(10 mg·kg^(-1))和中药低、中、高剂量组(龟羚帕安丸1,2,4 g·kg^(-1));各组给予右侧纹状体注射移植5μL NSCs悬液,空白对照组注射5μLPBS;灌胃给药,每日2次,连续28 d。免疫组化法检测PD大鼠中脑黑质的NSCs存活数以及Nurr1、Shh蛋白表达情况。结果与空白对照组比较,移植对照组的NSCs存活数、Nurr1及Shh蛋白表达水平明显升高(P <0.01)。与移植对照组比较,各治疗组的中脑黑质NSCs存活数以及Nurr1、Shh蛋白表达明显升高(P <0.05,P <0.01)。结论龟羚帕安丸能够促进PD大鼠NSCs移植后的细胞存活,可能与其上调大鼠中脑黑质Nurr1、Shh蛋白表达水平有关。
Objective To observe the effect of Gui Ling Pa’an pill on neural stem cell (NSC) transplantation and the expression of Nurr1 and Shh in substantia nigra of rats in Parkinson’s disease (PD) model rats after NSC transplantation. Methods Sixty PD model rats induced by 6-hydroxydopamine injection were randomly divided into six groups:blank control group,NSC transplantation control group,Madopar group (10 mg·kg^-1),Gui Ling Pa’an pill groups (1.0,2.0,4.0 g·kg^-1). Five microliters of PBS were injected into the right striatum of each rat of the blank control group. The other five groups were injected with same amount of NSC suspension into the right striatum of the rats. Rats in NSC transplantation control group were given normal saline with the same volume,all with a course of 28 days. The number of BrdU marked cells and the protein expression of Nurr1 and Shh in substantia nigra were assessed by immunohistochemistry. Results Compared with blank control group,the survival number of NSCs and the protein expression of Nurr1 and Shh in substantia nigra of NSC transplantation control group were significantly increased (P<0.01). Compared with NSC transplantation group,the number of NSCs survival cells and the protein expression of Nurr1 and Shh protein in substantia nigra tissue were of treatment groups significantly increased (P<0.05,P<0.01). Conclusion The mechanism of Gui Ling Pa’an pill increasing the survival ofNSCs in PD rats after NSC transplantation was proposed to be relevant to upregulating the Nurr1 and Shh expression.
作者
常学辉
张良芝
黎民
CHANG Xuehui;ZHANG Liangzhi;LI Min(The Second Clinical Medical College of Henan College of Traditional Chinese Medicine,Zhengzhou 450002 Henan,China;Basic Medical College of Henan College of Traditional Chinese Medicine,Zhengzhou 450008 Henan,China)
出处
《中药新药与临床药理》
CAS
CSCD
北大核心
2018年第6期702-706,共5页
Traditional Chinese Drug Research and Clinical Pharmacology
基金
河南省高等学校重点科研项目(16A360019)
